When to Start Apixaban (Eliquis) in Atrial Fibrillation Patients Already on Aspirin
Stop aspirin immediately and start apixaban now—there is no benefit to continuing aspirin once you initiate anticoagulation for atrial fibrillation, and dual therapy significantly increases bleeding risk without improving outcomes.
Immediate Transition Strategy
The FDA label for Eliquis provides clear guidance: discontinue aspirin and begin apixaban at the usual time of the next aspirin dose 1. There is no need for overlap, bridging, or gradual transition. The 2024 ESC guidelines explicitly state that antiplatelet therapy beyond 12 months is not recommended in stable patients treated with oral anticoagulation due to lack of efficacy and increased major bleeding 2.
Standard Apixaban Dosing for Atrial Fibrillation
- 5 mg twice daily for most patients
- 2.5 mg twice daily if patient has ≥2 of the following:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL 1
The Evidence Against Aspirin Continuation
The AUGUSTUS trial definitively showed that aspirin added to anticoagulation increases bleeding without reducing thrombotic events. When comparing apixaban alone versus apixaban plus aspirin, the aspirin group had significantly higher bleeding rates (2.4% vs 1.3% per year for any bleeding) with no reduction in stroke or myocardial infarction 3. The ARISTOTLE trial confirmed that apixaban reduces stroke and major bleeding compared to warfarin regardless of concomitant aspirin use, but the absolute bleeding rates were consistently higher when aspirin was added 4.
Special Clinical Scenarios
If Patient Has Recent ACS or PCI
This is the only situation where brief aspirin continuation might be considered. The 2020 ACC Expert Consensus recommends:
- Early cessation of aspirin (≤1 week) after uncomplicated PCI
- Continue apixaban with clopidogrel (P2Y12 inhibitor) for up to 12 months
- This applies when thrombosis risk is low or bleeding risk is high 3
After 12 months post-PCI or ACS, stop all antiplatelet therapy and continue apixaban alone 2.
If Patient Has Chronic Coronary or Vascular Disease
Stop aspirin and start apixaban alone. The 2024 ESC guidelines are unequivocal: antiplatelet therapy beyond 12 months is not recommended in stable patients with chronic coronary or vascular disease treated with oral anticoagulation 2. The bleeding risk outweighs any theoretical benefit.
If Patient Has History of Stroke/TIA
Start apixaban immediately and stop aspirin. Recent evidence from the ARTESiA subgroup analysis shows that patients with subclinical atrial fibrillation and prior stroke/TIA benefit substantially from apixaban over aspirin, with a 7% absolute risk reduction in stroke over 3.5 years versus only 3% absolute increase in major bleeding 5. For clinical atrial fibrillation with prior stroke, the benefit is even more pronounced—apixaban reduced stroke by 71% (HR 0.29) compared to aspirin in the AVERROES subgroup analysis 6.
Risk Stratification: Who Benefits Most
Use the CHA2DS2-VASc score to assess stroke risk and guide the urgency of transition:
- CHA2DS2-VASc >4: Highest priority—stroke risk 2.2% per year on aspirin vs 1.0% on apixaban. Apixaban prevents 1.28 strokes per 100 patient-years while causing only 0.68 major bleeds 7
- CHA2DS2-VASc = 4: Intermediate group—benefits and risks more balanced, but apixaban still preferred
- CHA2DS2-VASc <4: Lower stroke risk, but apixaban still superior to aspirin for stroke prevention 7
Common Pitfalls to Avoid
Do not continue aspirin "just in case"—this is the most common error. The data consistently show harm without benefit 2, 3, 4
Do not delay apixaban initiation—every day on aspirin instead of apixaban exposes the patient to higher stroke risk without reducing bleeding 5, 6
Do not use bridging anticoagulation—simply switch directly from aspirin to apixaban 1
Watch for NSAIDs—NSAID use increases major bleeding risk 10-fold in patients on apixaban (HR 10.25). Counsel patients to avoid NSAIDs 8
Bleeding Risk Considerations
While apixaban does increase major bleeding compared to aspirin (1.71% vs 0.94% per year), most bleeding events are non-critical gastrointestinal bleeds rather than intracranial hemorrhages. Rates of fatal bleeding (0.10% vs 0.16%) and intracranial bleeding (0.33% vs 0.40%) are actually similar or lower with apixaban 8. The bleeding that does occur with apixaban is less likely to be at critical sites compared to aspirin (27.9% vs 46.8% critical site bleeding) 8.
Bottom line: Start apixaban today, stop aspirin today, unless the patient had PCI within the past week—in which case stop aspirin within 1 week and continue with apixaban plus clopidogrel.